Johnson & Johnson (NYSE:JNJ) Position Boosted by MGO One Seven LLC

MGO One Seven LLC raised its stake in Johnson & Johnson (NYSE:JNJ - Free Report) by 10.8% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 76,442 shares of the company's stock after purchasing an additional 7,454 shares during the period. MGO One Seven LLC's holdings in Johnson & Johnson were worth $11,055,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also made changes to their positions in the company. IFS Advisors LLC increased its position in shares of Johnson & Johnson by 138.9% in the 4th quarter. IFS Advisors LLC now owns 172 shares of the company's stock valued at $25,000 after purchasing an additional 100 shares during the last quarter. WealthTrak Capital Management LLC purchased a new position in Johnson & Johnson in the fourth quarter valued at $26,000. Mountain Hill Investment Partners Corp. acquired a new stake in Johnson & Johnson in the fourth quarter valued at $29,000. Bay Harbor Wealth Management LLC purchased a new stake in Johnson & Johnson during the 4th quarter worth about $32,000. Finally, Conquis Financial LLC acquired a new position in shares of Johnson & Johnson during the 4th quarter worth about $33,000. Hedge funds and other institutional investors own 69.55% of the company's stock.

Johnson & Johnson Stock Performance

Shares of Johnson & Johnson stock traded down $0.39 during trading hours on Friday, reaching $154.54. The company's stock had a trading volume of 8,642,889 shares, compared to its average volume of 7,921,500. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.86 and a current ratio of 1.11. Johnson & Johnson has a one year low of $140.68 and a one year high of $169.99. The company's 50 day simple moving average is $159.49 and its 200 day simple moving average is $154.92. The stock has a market cap of $372.42 billion, a P/E ratio of 23.24, a price-to-earnings-growth ratio of 2.56 and a beta of 0.49.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its earnings results on Tuesday, April 15th. The company reported $2.77 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.59 by $0.18. The company had revenue of $21.89 billion for the quarter, compared to analysts' expectations of $21.65 billion. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. As a group, analysts expect that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 10th. Shareholders of record on Tuesday, May 27th will be paid a $1.30 dividend. The ex-dividend date is Tuesday, May 27th. This represents a $5.20 annualized dividend and a dividend yield of 3.36%. This is a positive change from Johnson & Johnson's previous quarterly dividend of $1.24. Johnson & Johnson's dividend payout ratio (DPR) is presently 57.84%.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on the company. Royal Bank of Canada restated an "outperform" rating and set a $181.00 target price on shares of Johnson & Johnson in a research note on Wednesday, April 16th. Barclays reduced their price objective on shares of Johnson & Johnson from $166.00 to $165.00 and set an "equal weight" rating for the company in a research report on Thursday, April 17th. Wells Fargo & Company cut their price target on shares of Johnson & Johnson from $166.00 to $152.00 and set an "equal weight" rating on the stock in a research note on Thursday, January 23rd. StockNews.com upgraded shares of Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a research note on Saturday, January 25th. Finally, Sanford C. Bernstein reiterated a "market perform" rating on shares of Johnson & Johnson in a research report on Wednesday, April 16th. Nine equities research analysts have rated the stock with a hold rating, eight have given a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $171.82.

Insider Activity

In related news, VP Robert J. Decker sold 6,999 shares of the firm's stock in a transaction that occurred on Tuesday, February 25th. The shares were sold at an average price of $165.88, for a total transaction of $1,160,994.12. Following the transaction, the vice president now owns 21,001 shares in the company, valued at $3,483,645.88. This trade represents a 25.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Timothy Schmid sold 403 shares of the company's stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total value of $62,928.45. Following the completion of the sale, the executive vice president now owns 15,098 shares of the company's stock, valued at $2,357,552.70. This trade represents a 2.60 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 0.16% of the company's stock.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.